AzTrials
AzTrials

Peripheral Arterial DiseasePrEPAIDNCT03204825

Pain Management and Patient Education for Physical Activity in Intermittent Claudication (PrEPAID)

A study testing Active TENS and Patient-Centred Education in people with Peripheral Arterial Disease and Intermittent Claudication, run by Glasgow Caledonian University at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Peripheral Arterial disease is a common condition which causes narrowing of the arteries. The most common symptom that patients with PAD experience is Intermittent Claudication (IC), pain in the lower limb(s) on exertion, which is relieved by rest. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Active TENS and Patient-Centred Education
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
95 participants
Where
1 siteUnited Kingdom
Study dates
1 Aug 2017to 24 Mar 2020
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Clinical diagnosis of symptomatic Peripheral Arterial Disease (PAD) including resting Ankle Brachial Pressure Index (ABPI) <0.9 in at least one leg
  • Stable IC for ≥3 months
  • Walking limited primarily by claudication
  • Able to exercise on a treadmill
  • Able to read and speak English to a level allowing satisfactory completion of the study procedures
  • Able to provide written informed consent for participation

Who cannot join

  • Planned surgical or endovascular intervention for PAD within the next 3 months
  • Critical limb ischaemia
  • The presence of any absolute contraindications to exercise testing/training as defined by the American College of Sports Medicine (ACSM)
  • Previous experience of using TENS/ structured patient education for PAD
  • Contraindications to TENS (including epilepsy, dermatological conditions, indwelling electrical pumps/pacemakers) and inability to apply TENS independently.
  • Patients who require walking aids including artificial limbs
Show all 11Show fewer
  • Major surgery, myocardial infarction or stroke/ Transient Ischaemic Attack (TIA) in the previous 6 months
  • Co-morbidities that cause pain or limit walking to a greater extent than IC (e.g. severe arthritis)
  • >20% variation in baseline ACD on treadmill
  • Severe peripheral neuropathies above the ankle.
  • Participation in another research protocol

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • Clinical Research Facility, Queen Elizabeth University Hospital

    Glasgow, Strathcylde, G51 4TF

Other trials in United Kingdom

About this study

Official title: Pain Management and Patient Education for Physical Activity in Intermittent Claudication (PrEPAID): Feasibility Randomised Controlled Trial

Peripheral Arterial disease is a common condition which causes narrowing of the arteries. The most common symptom that patients with PAD experience is Intermittent Claudication (IC), pain in the lower limb(s) on exertion, which is relieved by rest. IC reduces patients' quality of life (QoL) by limiting their ability to walk and engage in daily activities. Regular exercise and physical activity (PA) are central to the management of PAD and help to improve walking distances and reduce the risks associated with PAD such as heart attack and stroke. However, exercise and PA in this population is often limited due to pain. Investigators have shown that Transcutaneous Electrical Nerve Stimulation (TENS) can help to reduce pain and increase walking distance in patients with PAD. Investigators have also shown that educating patients about their condition and helping them to set goals has the potential to increase PA, and quality of life. This study will examine the feasibility of designing a definitive trial that investigates whether TENS can improve the physical activity of patients with PAD when delivered alone and/or alongside a patient education programme.

Read the detailed description

Peripheral Arterial disease (PAD) affects 2.7 million people in the United Kingdom (UK). The most common symptom that patients experience is Intermittent Claudication (IC), which is pain in the buttock, calf or thigh precipitated by exercise and relieved by rest. The underlying cause of PAD is atherosclerosis, which leads to arterial stenosis, inadequate blood flow and build-up of lactic acid during exercise. Patients with IC have impaired quality of life due to reduced physical capacity. Furthermore, due to the diffuse nature of atherosclerosis and the involvement of other arterial beds, they have 3-4 times increased mortality compared to age and sex matched controls.

Patients with symptomatic PAD should receive the same secondary prevention management as patients with symptomatic coronary artery disease. Improving daily physical activity (PA) is particularly important in individuals with IC as lower PA levels have been recognised as a strong predictor of increased morbidity and mortality in this population. Current National Institute for Health and Care Excellence (NICE) guidelines recommend the use of supervised exercise programmes (SEPs), encouraging patients "to exercise to the point of maximal pain", as first line treatment. SEPs has been shown to be cost-effective when compared to other treatment options such as endovascular intervention and surgical revascularisation. However, while systematic reviews show that SEPs lead to a significant improvement in the absolute walking distances of patients with IC on a treadmill, it is unclear if this is sustained or leads to improvement in daily PA. Furthermore, due to the considerable extra resources required to deliver the recommended 3 months exercise programme (30-45 minutes 3x weekly), SEPs are not always routinely available to National Health Service (NHS) patients, and time and travel costs tend to lead to low patient uptake and high attrition rates. Therefore, investigating the feasibility of using low-cost, patient-centred interventions that can support increased PA is warranted.

Lack of self-efficacy, attributed to poor understanding of the disease and uncertainty regarding the importance of exercise, has been shown to be a major barrier to exercise uptake in this population. Educating patients with IC about their disease pathology and the benefits of walking is key to enhancing success of secondary prevention strategies for people with IC. Investigators recently piloted a structured, patient-centred education intervention (SEDRIC) with the specific aim of educating patients with IC about their condition, improving patient ownership, and promoting self-managed walking. In addition to improved treadmill walking distances, investigators found out that there was a trend for patients to increase their daily PA.

For patients with IC to gain benefits of secondary prevention, exercising beyond the point when pain occurs is recommended, representing another barrier to engagement in PA. Despite this, investigators' systematic review found that pain management as a route to facilitate exercise and PA has rarely been explored. Recent interest has focused on the use of TENS (a low-cost, non-invasive pain management device) to improve angiogenesis, muscle function, pain and walking distances in patients with IC. TENS has a strong placebo effect in pain conditions, and testing effectiveness against placebo is advocated. In a proof-of-concept pilot study, Investigators demonstrated that TENS could significantly improve pain and increase treadmill walking distances above placebo levels. Our exploratory study also established that home use of TENS was both acceptable and provided self-reported improvement in PA in individuals with IC.

Although patient-centred education (SEDRIC) and TENS have both demonstrated potential to improve daily PA in people with IC, the use of these components in combination has not previously been evaluated. Investigators therefore propose a 2 x 2 (TENS versus placebo TENS x SEDRIC versus no additional education) feasibility Randomised Controlled Trial (RCT) that will compare use of TENS against placebo TENS with and without a patient-centred education programme.

Investigators have conducted a series of pilot studies underpinning both aspects of the intervention. Investigators have demonstrated in an experimental lower limb ischaemic pain model in healthy volunteers (n=28) that TENS significantly reduced onset of pain (by 29 seconds; 23%), tolerance of pain (by 203 seconds; 53%) and the pain endurance (by 173 seconds; 67%), compared to placebo TENS. Following this, in a proof-of-concept pilot study, investigators demonstrated that TENS when applied to patient with IC exercising on a treadmill (n=40) significantly improved absolute claudication distance (ACD) above placebo levels (approx. mean individual increase in ACD of 40%, p=.025, r= .53). Our phase 2 study also established that home use of TENS was both acceptable and provided self-reported improvement in PA in individuals with IC. Investigators have not assessed the ability of TENS to improve ACD when used during daily life.

Similarly, this research group developed and piloted SEDRIC, a structured, patient-centred education intervention with the specific aim of educating patients about their condition, improving patient ownership, and promoting self-managed walking. Investigators found that in patients with PAD (n=14), treadmill walking distances (30%) and quality of life (32%) improved from baseline after 6 weeks of structured education, and there was a trend for patients to increase their daily PA (approx. 8% change from baseline).

The aim is to determine the feasibility of electrical stimulation via a low-cost CE-marked device used within a patient centred education programme to improve walking distances in patients with PAD.

The following research questions will be answered by this project:

  1. What is the feasibility (i.e. recruitment and retention rates, adherence, safety, sample size for a definitive trial, potential for effectiveness) of conducting a definitive RCT comparing TENS with and without patient-centred education?
  2. How acceptable are TENS and patient-centred education as interventions on their own or in combination in patients with IC?
Being tested
Active TENS, Patient-Centred Education, Placebo TENS
Keywords
Patient education, Pain management, Transcutaneous electrical nerve stimulation, Physical activity, Feasibility
Medical subject headings
Peripheral Arterial Disease, Intermittent Claudication, Agnosia, Motor Activity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Active TENSDevice

    Also called TENS, TNS, Transcutaneous Nerve Stimulation, Transcutaneous Electrical Nerve Stimulation

    TENS is a form of electrical stimulation that provides symptomatic pain relief that is used extensively within the health-care setting. It is a non-invasive modality; packaged in a small, portable unit that is easy to apply via small electrodes placed on the skin.

  • Patient-Centred EducationBehavioural

    Also called Education, SEDRIC, Structured patient-centred education intervention

    Group education for patients with peripheral arterial disease and intermittent claudication about their condition, improving patient ownership, and promoting self-managed walking

  • Placebo TENSDevice

    Also called P-TENS, Placebo Transcutaneous Electrical Nerve Stimulation

    TENS device use with setting so that the stimulation delivered is ineffective

Study groups in NCT03204825
Study groupRoleWhat they receive
Active TENSExperimentalParticipants in the TENS groups will be provided with a TENS machine and training at the baseline visit to the Clinical research Facility (CRF). They will be instructed to use it daily as their symptoms require for 6 weeks. The active group will receive High Frequency-TENS (120 Hz, 200µs and a patient-determined intensity of ''strong but comfortable'').
Receives: Device: Active TENS
Placebo TENSPlacebo comparatorPlacebo TENS : Participants will receive the same model, programmed settings and instructions for use as those in the active group except that the device will be set to an ineffective stimulation (120 Hz, 200µs and a patient-determined intensity of '6mA). For the purpose of blinding, participants will be told that different dosages of TENS are being tested, some of which where the stimulation might not be perceivable even though the device is working.
Receives: Device: Placebo TENS
Patient-Centred EducationExperimentalPatient-Centred Education : a one-off three-hour workshop of structured group education (4-5 persons in each group) and three 2-weekly phone calls. The aim will be to modify patients' illness beliefs and perceptions about IC/PAD by educating them on disease pathology and management philosophy. After the workshop, each patient will be supported to set goals for walking, develop an action plan regarding how these goals will be met and encouraged to repeat this process for each new walking goal.
Receives: Behavioral: Patient-Centred Education
Patient-Centred Education + Active TENSExperimentalCombination of Patient-Centred Education arm and Active TENS arm.
Receives: Device: Active TENS; Behavioral: Patient-Centred Education

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Absolute Claudication Distance (ACD) in Meters From Baseline

    Maximal walking distance on graded treadmill test

    Measured: Baseline, 6 weeks (post-intervention), 18 weeks (follow-up)

  2. Recruitment Rates

    Measure recruitment rates (ratio of patients who consent to participate to potentially eligible patient recorded via the study screening log

    Measured: Recruitment

  3. Participant Retention Rate

    Ratio of patients who completed the intervention and outcome assessment to the patient who consented

    Measured: End of study (18 weeks)

  4. Adverse Events

    Record defined adverse events in all groups

    Measured: End of study (18 weeks)

  5. Uptake of Interventions

    Measure uptake of intervention via log of TENS use and attendance at education session and follow up phone calls

    Measured: End of study (18 weeks)

Secondary outcomes (13)
  1. Change in Initial Claudication Distance (ICD) in Meters From Baseline

    Onset distance of claudication pain on graded treadmill test

    Measured: Baseline, 6 weeks (post-intervention), 18 weeks (follow-up)

  2. Change in Daily Number of Steps

    Change in daily number of steps (activpal step counts)

    Measured: Baseline, 6 weeks (post-intervention), 18 weeks (follow-up)

  3. Change in Total Number of Upright Events Per Day

    Total number of upright events per day (activpal upright even count)

    Measured: Baseline, 6 weeks (post-intervention), 18 weeks (follow-up)

  4. Change in Total Number of Walking Events Per Day

    Total number of walking events per day (activpal walking event counts)

    Measured: Baseline, 6 weeks (post-intervention), 18 weeks (follow-up)

  5. Change in Event-based Claudication Index

    Event-based claudication index (ratio of walking events to upright events) participants undertake in a day.

    Measured: Baseline, 6 weeks (post-intervention), 18 weeks (follow-up)

  6. Intermittent Claudication Questionnaire (ICQ)

    Disease specific quality of life questionnaire. ICQ scores range from 0 to 100, with lower scores representing better health status and less impact of claudication

    Measured: Baseline, 6 weeks (post-intervention), 18 weeks (follow-up)

  7. Short-Form 36 Questionnaire- Physical Component

    Generic quality of life questionnaire, physical domain. The SF-36 Physical Component Summary (PCS) ranges from 0-100, with higher scores representing better outcomes.

    Measured: Baseline, 6 weeks (post-intervention), 18 weeks (follow-up)

  8. McGill Pain Questionnaire (MPQ) Pain Rating Index (PRI)

    Pain quality questionnaire. The MPQ-PRI ranges from 0-78, with lower scores representing less pain and higher scores representing worse pain.

    Measured: Baseline, 6 weeks (post-intervention), 18 weeks (follow-up)

  9. Visual Analogue Scale (VAS)

    Average Pain intensity in the past 7 days. The average pain intensity VAS ranges from 0-100 mm, with lower scores indicating less pain and better outcomes.

    Measured: Baseline, 6 weeks (post-intervention), 18 weeks (follow-up)

  10. Brief Illness Perception Questionnaire (IPQ)

    The Brief IPQ uses 0-10 scales. Higher scores indicate worse perceptions (greater perceived consequences, concern, emotional impact, chronicity).

    Measured: Baseline, 6 weeks (post-intervention), 18 weeks (follow-up)

  11. Geriatric Depression Scale (Short Form) (GDS-SF)

    Depression questionnaire. The GDS-SF ranges 0-15, with higher scores reflecting more depressive symptoms.

    Measured: Baseline, 6 weeks (post-intervention), 18 weeks (follow-up)

  12. Pain Self-Efficacy Questionnaire (PSEQ)

    The PSEQ total score ranges from 0-60, with higher scores indicating better pain self-efficacy and more positive outcomes.

    Measured: Baseline, 6 weeks (post-intervention), 18 weeks (follow-up)

  13. SF-36 Mental Component Score

    SF-36 Quality of life scale - mental component. The SF-36 MCS ranges 0-100 (or norm-based mean 50, SD 10), with higher scores representing better outcomes.

    Measured: Baseline, end of intervention and follow-up

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Jul 2017
  2. Study start1 Aug 2017
  3. Primary completion24 Mar 2020
  4. Study completion24 Mar 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Model description
2x2 randomised feasibility controlled trial blinded for primary outcome
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
95 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03204825
Sponsor's protocol ID
16 044
Acronym
PrEPAID
Status last verified
Sep 2025
First submitted
25 Apr 2017
Last updated
6 Oct 2025
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Abaraogu UO, Dall PM, Seenan CA. Patient education interventions to improve physical activity in patients with intermittent claudication: a protocol for a systematic mixed-studies review. BMJ Open. 2016 May 20;6(5):e011405. doi: 10.1136/bmjopen-2016-011405.

    PubMed 27207628
  • Tew GA, Humphreys L, Crank H, Hewitt C, Nawaz S, Al-Jundi W, Trender H, Michaels J, Gorely T. The development and pilot randomised controlled trial of a group education programme for promoting walking in people with intermittent claudication. Vasc Med. 2015 Aug;20(4):348-57. doi: 10.1177/1358863X15577857. Epub 2015 Apr 9.

    PubMed 25858012
  • Abaraogu UO, Ezenwankwo EF, Dall PM, Seenan CA. Living a burdensome and demanding life: A qualitative systematic review of the patients experiences of peripheral arterial disease. PLoS One. 2018 Nov 15;13(11):e0207456. doi: 10.1371/journal.pone.0207456. eCollection 2018.

    PubMed 30440040
  • Abaraogu U, Ezenwankwo E, Dall P, Tew G, Stuart W, Brittenden J, Seenan C. Barriers and enablers to walking in individuals with intermittent claudication: A systematic review to conceptualize a relevant and patient-centered program. PLoS One. 2018 Jul 26;13(7):e0201095. doi: 10.1371/journal.pone.0201095. eCollection 2018.

    PubMed 30048501
  • Abaraogu UO, Dall PM, Seenan CA. The Effect of Structured Patient Education on Physical Activity in Patients with Peripheral Arterial Disease and Intermittent Claudication: A Systematic Review. Eur J Vasc Endovasc Surg. 2017 Jul;54(1):58-68. doi: 10.1016/j.ejvs.2017.04.003. Epub 2017 May 18.

    PubMed 28528678
  • Seenan C, Abaraogu U, Dall PM, Gilmour L, Tew G, Stuart W, Elders A, Brittenden J. Pain management and patient education interventions to increase physical activity in people with intermittent claudication (PrEPAID): a feasibility randomised controlled trial in the UK. BMJ Open. 2025 Jul 22;15(7):e105563. doi: 10.1136/bmjopen-2025-105563.

    PubMed 40701603
  • Abaraogu UO, Dall PM, Brittenden J, Stuart W, Tew GA, Godwin J, Seenan CA. Efficacy and Feasibility of Pain management and Patient Education for Physical Activity in Intermittent claudication (PrEPAID): protocol for a randomised controlled trial. Trials. 2019 Apr 16;20(1):222. doi: 10.1186/s13063-019-3307-6.

    PubMed 30992033

Questions about this trial

What is this clinical trial studying?

A study testing Active TENS and Patient-Centred Education in people with Peripheral Arterial Disease and Intermittent Claudication, run by Glasgow Caledonian University at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 6 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 6 Oct 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Absolute Claudication Distance (ACD) in Meters From Baseline (time frame: Baseline, 6 weeks (post-intervention), 18 weeks (follow-up)). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03204825, which also lists 7 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Oct 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in